These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32755234)

  • 1. Macular atrophy development in neovascular age-related macular degeneration.
    Călugăru D; Călugăru M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP307-NP308. PubMed ID: 32755234
    [No Abstract]   [Full Text] [Related]  

  • 2. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.
    Min JK; Lee S; Park JH; Woo JM; Yang HS
    Acta Ophthalmol; 2018 Jun; 96(4):e546-e547. PubMed ID: 29068524
    [No Abstract]   [Full Text] [Related]  

  • 9. First-dose effects with intravitreal aflibercept in wet age-related macular degeneration: a post-hoc analysis of VIEW-1 and VIEW-2 phase 3 studies.
    Kherani A; Brunck LR; Katz TA; Galic J
    Can J Ophthalmol; 2021 Aug; 56(4):268-269. PubMed ID: 33249110
    [No Abstract]   [Full Text] [Related]  

  • 10. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
    Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen For Neovascular Age-Related Macular Degeneration-The Aries Study: A Randomized Clinical Trial-Erratum.
    Retina; 2022 Sep; 42(9):e43. PubMed ID: 35994588
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.
    Heussen FM; Shao Q; Ouyang Y; Joussen AM; Müller B
    Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):909-15. PubMed ID: 24362854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified observe-and-plan regimen using aflibercept for neovascular age-related macular degeneration.
    Jeong S; Ryu G; Sagong M
    Acta Ophthalmol; 2021 Dec; 99(8):e1535-e1536. PubMed ID: 33769696
    [No Abstract]   [Full Text] [Related]  

  • 20. Switch of anti-vascular growth factor agent from aflibercept to bevacizumab; outcomes in chronic wet age-related macular degeneration.
    Granstam E; Sjövall K; Rosén M
    Acta Ophthalmol; 2022 Dec; 100(8):e1772-e1773. PubMed ID: 35587775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.